SCHEMBL6080906

SCHEMBL6080906

COc1c(Cl)cc(Cl)c2c(O)c(C)c(C(=O)O)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.42
KMO O15229 1/20 0.37
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 1/20 0.36
GPR35 Q9HC97 2/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
TGM2 P21980 1/20 0.35
PDE4A P27815 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
GALK1 P51570 1/20 0.35
BLM P54132 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078796 0.84 MAPT (0.41) KMOKDM4EALDH1A1HSD17B10GPR35
SCHEMBL6079523 0.82 MRGPRX4 (0.43) KDM4ELMNAMAPTSMN1; SMN2L3MBTL1
SCHEMBL6593961 0.75 TPMT (0.48) TPMTKDM4EALDH1A1HSD17B10GPR35
SCHEMBL25925492 0.70 TPMT (0.51) TPMTKDM4EALDH1A1HSD17B10KMT2A
SCHEMBL6081049 0.69 MAPT (0.42) TPMTKMOKDM4EALDH1A1HSD17B10
SCHEMBL6080302 0.69 GPR35 (0.44) KDM4EALDH1A1GPR35MAPK1PDE4B
SCHEMBL6080902 0.69 NQO2 (0.50) TPMTKDM4EALDH1A1PDE4DHPGD
SCHEMBL14354477 0.68 TPMT (0.49) TPMTKMOKDM4EALDH1A1HSD17B10
SCHEMBL6080250 0.68 DHODH (0.41) KDM4EALDH1A1KMT2AMEN1LMNA
SCHEMBL6081119 0.68 RNASEH1 (0.44) KDM4EALDH1A1GPR35KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL TPMT 492/4885KMO 91/4885KDM4E 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.